Evidence map›Paper›PMID 33659041›Full record

ArticleOncotarget2021

Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model.

Ali H Zaidi, Ronan J Kelly, Anastasia Gorbunova, Ashten N Omstead, Madison S Salvitti, Ping Zheng, Juliann E Kosovec, Soyoung Lee, Shahin Ayazi, Laila Babar and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. The tumor cell-intrinsic cGAS-STING pathway is associated with the high density of CD8Esophagus : official journal of the Japan Esophageal Society · 2024
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Ali H ZaidiEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Ronan J KellyDepartment of Hematology and Oncology, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.
Anastasia GorbunovaEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Ashten N OmsteadEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Madison S SalvittiEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Ping ZhengEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Juliann E KosovecEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Soyoung LeeDepartment of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA, USA.
Shahin AyaziEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Laila BabarEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Gene G FinleyEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Ajay GoelDepartment of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope, Monrovia, CA, USA.
Blair A JobeEsophageal and Lung Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Lung Institute · USAllegheny Health Network · USBaylor University Medical Center · USCity of Hope · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal adenocarcinoma (EAC) is a deadly disease with limited treatment options. STING is a transmembrane protein that activates transcription of interferon genes, resulting in stimulation of APCs and enhanced CD8+ T-cell infiltration. The present study evaluates STING agonists, alone and in combination with radiation to determine durable anticancer activity in solid tumors. MATERIALS AND

methodsEsophagojejunostomy was performed on rats to induce reflux leading to the development of EAC. At 32 weeks post operatively, rats received intratumorally either 50 μg STING (ADU-S100) or placebo (PBS), +/- 16Gy radiation. Drug activity was evaluated by pre- and post- treatment MRI, histology, immunofluorescence and RT-PCR.

resultsMean MRI tumor volume decreased by 30.1% and 50.8% in ADU-S100 and ADU-S100 + radiation animals and increased by 76.7% and 152.4% in placebo and placebo + radiation animals, respectively (

conclusionsADU-S100 +/- radiation exhibits potent antitumor activity and a promising immunomodulatory profile in a

Indexed as

CD8+ T-cellsesophageal adenocarcinomaIFNβPD-L1STING

Identifiers

PMID33659041
PMCPMC7899550
OpenAlexW3133405534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.